Global Colon Cancer Association (GCCA) posted on Linkedin:
“Colorectal cancer is only the third most commonly diagnosed cancer in Mexico — but it has become the leading cause of cancer death in the country.
This disparity points to gaps in screening access, late-stage diagnosis, and equitable access to precision medicine. For the third consecutive year, the Global Colon Cancer Association (GCCA) traveled to Mexico City to address these challenges alongside Fundación FUTEJE and the From Testing to Targeted Treatments (FT3) initiative.
Over the course of a full week, the delegation met with policymakers at the Cámara de Diputados (Mexican Congress), clinicians at Hospital Juárez de México and the National Cancer Institute (INCan), business leaders at CONCAMIN (CONFEDERACIÓN DE CÁMARAS INDUSTRIALES, MÉXICO), and representatives from nine pharmaceutical companies — including Astellas Pharma, Boehringer Ingelheim, Bristol Myers Squibb, Johnson & Johnson, Merck, Pfizer, Servier, Takeda, and Teva Pharmaceuticals — at a Pfizer-hosted roundtable.
A key outcome: a commitment to convene a May policy forum focused on expanding patient access to precision medicine for colorectal cancer in Mexico.”
Other articles from GCCA on OncoDaily.
